In Vivo Iontophoretic Administration of Ropinirole Hydrochloride

Journal of Pharmaceutical Sciences

Volumn 92, Issue 12, 2003, Pages 2441-2448

  Luzardo Alvarez, Asteria ^a   Delgado Charro, M Begoña ^b,c   Blanco Méndez, José ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Centre Interuniversitaire de Recherche et d'Enseignement   (France)

Author keywords

Iontophoresis; Parkinson's disease; Ropinirole HCl

Indexed keywords

ROPINIROLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; ELECTRIC CURRENT; ELECTRODE; IONTOPHORESIS; MALE; NONHUMAN; RAT; RAT STRAIN; SKIN; SKIN BIOPSY; WATER LOSS;

EID: 0344875531     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10502     Document Type: Article

References (31)

1. Delgado-Charro MB, Guy RH. 2001. Transdermal iontophoresis for drug delivery and non-invasive monitoring. STP Pharma Sci 11:403-414.
2. Green PG. 1996. Iontophoretic delivery of peptide drugs. J Controlled Release 41:33-48.
3. Scott ER, Phipps JB, Gyory JR, Padmanabhan RV. 2000. Electrotransport systems for transdermal delivery: A practical implementation of iontophoresis. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, pp 617-659.
4. Delgado-Charro MB, Guy RH. 1998. Iontophoresis of peptides. In: Berner B, Dinh SM, editors. Electronically controlled drug delivery. Boca Raton, FL: CRC Press, pp 129-157.
5. Phipps JB, Padmanabhan RV, Lattin GA. 1989. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci 78:365-369.
6. Padmanabhan RV, Phipps JB, Lattin GA, Sawchuk RJ. 1990. In vitro and in vivo evaluation of transdermal iontophoretic delivery of hydromorphone. J Controlled Release 11:123-135.
7. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF. 1997. Ropinirole for the treatment of early Parkinson's disease. Neurology 49:393-399.
8. Scharg DJ, Brooks E, Brunt D, Fuell A, Korczyn W, Poewe N, Quinn P, Rascol O, Stocchi F. The safety of Ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Neuropharmacology 21:169-175.
9. Matheson J, Spencer CM. 2000. Ropinirole. A review of its use in the management of Parkinson's disease. Drugs 60:115-137.
10. Korczyn AD, Brunt ER, Larsen JP. 1999. A 3-year randomised trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 53:364-370.
11. Danhof M, Van der Geest R, Van Laar T, Bodde HE. 1998. An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease. Adv Drug Del Rev 33:253-263.
12. Guy RH, Delgado-Charro MB, Kalia KN. 2001. Iontophoretic transport across the skin. Skin Pharmacol Appl Skin Phys 14(Suppl 1):35-40.
13. Marro D, Kalia YN, Delgado-Charro MB, Guy RH. 2001. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res 18:1701-1708.
14. Kasting GB, Keister JC. 1989. Application of electrodiffusion theory for a homogeneous membrane to ion iontophoretic transport trough skin. J Controlled Release 8:195-210.
15. Luzardo-Alvarez A, Delgado-Charro MB, Blanco-Méndez J. 2001. Iontophoretic delivery of ropinirole hydrochloride: Effect of current density and vehicle formulation. Pharm Res 18:1714-1720.
16. Torres-Molina F, Aristorena JC, Garcia-carbonell C, Granero L, Chesa-Jimenez J, Pla-Delfina J, Peris-Ribera JE. 1992. Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxicilline and antipyrine in the rat. Pharm Res 9:1587-1591.
17. Swagzdiz JE, Wittendorf RW, DeMarinis RM, Mico BA. 1986. Pharmacokinetics of dopamine-2 agonist in rats and dogs. J Pharm Sci 75:925-928.
18. Ramji JV, Keogh JP, Blake TJ, Broom C, Chenery RJ, Citerones DR, Lewis VA, Taylor AC, Yeulet SE. 1999. Disposition of ropinirole in animals and man. Xenobiotica 29:311-325.
19. Shargel L, Yu ABC. 1992. Applied biopharmaceutics and pharmacokinetics. Norwalk, CT: Appleton & Lange.
20. Slough CL, Spinelli MJ, Kasting GB. 1988. Transdermal delivery of etidronate (EHDP) in the pig via iontophoresis. J Membr Sci 35:161-165.
21. Phipps JB, Gyory JR. 1992. Transdermal ion migration. Adv Drug Del Rev 9:137-176.
22. Van der Geest R, Elshove DAR, Danhof M, Lavrijsen APM, Bodde HE. 1996. Non-invasive assessment of skin barrier integrity and skin irritation following iontophoretic current application in humans. J Controlled Release 41:205-213.
23. Riviere JE, Monteiro-Riviere NA, Inmmman AO. 1992. Determination of lidocaine concentrations in skin after transdermal iontophoresis: Effects of vasoactive drugs. Pharm Res 9:211-214.
24. Lopez-Castellano A, Guy RH, Delgado-Charro MB. 1999. Effect of area on the iontophoretic transport of phenylalanine and propranolol across the skin. Proc Int Symp Controlled Release Bioact Mater 26th, pp 405-406.
25. Kaye CM, Nicholls B. 2000. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 39:243-254.
26. Monteiro-Riviere NA. 1990. Altered epidermal morphology secondary to lidocaine iontophoresis: In vivo and in vitro studies in porcine skin. Fundam Appl Toxicol 15:174-185.
27. Anigbogu A, Patil S, Singh P, Liu P, Dinh S, Maibach H. 2000. An in vivo investigation of the rabbit skin responses to transdermal iontophoresis. Int J Pharm 200:195-206.
28. Fouchard D, Hueber F, Teillaud E, Marty JP. 1997. Effects of iontophoretic current flow on hairless rat skin in vivo. J Controlled Release 49:89-94.
29. Brand RM, Singh P, Aspe-Carranza PE, Maibach HI, Guy RH. 1997. Acute effects of iontophoresis on human skin in vivo: Cutaneous blood flow and transepidermal water loss measurements. Eur J Pharm Biopharm 43:133-138.
30. Aaron C, Quesnel MJ. 1978. L'utilisation du célestène en ionisation dans le traitement des affections rhumatologiques. Semin Hop Paris 54:1091-1094.
31. Ledger PW. 1992. Skin biological issues in electrically enhanced transdermal delivery. Adv Drug Del Rev 9:289-307.